-
Markets
-
Equities
Sustainable finance2025 Euronext ESG Trends ReportRead moreA data-driven snapshot of how Euronext-listed companies are advancing their Environmental, Social and Governance (ESG) practices.
-
Indices
Access the white paperInvesting in the future of Europe with innovative indicesRead moreThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
ETFs
The European market place for ETFsEuronext ETF EuropeRead moreInvestors benefit from a centralised market place that will not only bring transparency but also better pricing due to the grouping of liquidity.
- Funds
-
Fixed Income
European Defence BondsGroupe BPCE lists the first bondRead moreFirst financial institution in Europe to issue a bond dedicated to the defence sector
- Structured Products
-
Derivatives
Where European Government Bonds Meet the FutureFixed Income derivativesRead moreTrade mini bond futures on main European government bonds
-
Commodities
- Overview
- Quotes snapshot
- Power Derivatives
- Milling Wheat derivatives
- Corn derivatives
- Spread contracts
- Rapeseed derivatives
- Durum Wheat derivatives
- Salmon derivatives
- Delivery & settlement
- Specifications & arrangements
- Commitments of Traders (CoT) report
- Commodity brokers
Building a sustainable and liquid power derivatives market.Euronext Nord Pool Power FuturesRead moreEuronext and Nord Pool, the European power exchange, announced the launch of a dedicated Nordic and Baltic power futures market.
-
Resources
Designed to help students navigate the complexities of financial marketsEuronext Trading gameRead moreJoin the Euronext Trading Game and step into capital markets. Learn from today’s leaders, explore sustainable opportunities, and trade with confidence.
Arctic Bioscience - Achieves significant vision improvement in Clinical Glaucoma Study
18 Aug 2025 10:28 CEST
Issuer
Arctic Bioscience AS
Arctic Bioscience today announced that a clinical study published
in International Ophthalmology demonstrated that daily supplementation with
ROMEGA® herring caviar oil resulted in a statistically significant improvement
in the visual field measure Mean Deviation (MD) in patients with primary open
-angle glaucoma (POAG) and controlled intraocular pressure (IOP). No adverse
events were observed, and the treatment was well tolerated.
About the study
The three-month study included 50 patients. The intervention group received one
ROMEGA® capsule (500mg) daily. Results showed a clear improvement in MD values
in the intervention group (p = 0.01) compared to baseline, while no similar
improvement was observed in the control group. Best-corrected visual acuity and
retinal nerve fiber layer thickness remained stable, and intraocular pressure
was maintained.
Next steps
"These findings suggest that ROMEGA® may be a safe and potentially effective
adjunct to protect vision in glaucoma patients, even when IOP is already
controlled. We are now planning larger, randomized studies to confirm these
promising results", says Hogne Hallaråker, CSO in Arctic Bioscience.
Link for more info: https://pmc.ncbi.nlm.nih.gov/articles/PMC12279572/
For more information, please contact:
Christer L. Valderhaug
CEO
Phone: +47 920 84 601
E-mail: christer@arctic-bioscience.com
Hogne Hallaråker
CSO
Phone: +47 481 20 388
E-mail: hogne@arctic-bioscience.com
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing
pharmaceutical and nutraceutical products based on unique bioactive marine
compounds.
The company is developing HRO350 - a novel oral drug candidate. HRO350 is being
developed for treatment of patients with mild-to-moderate psoriasis. This is a
large patient group in need of new effective medicines with beneficial safety
profile.
Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as
well as finished goods under the ROMEGA® brand.
Arctic Bioscience is led by a highly skilled team of talents with diverse and
highly relevant background.
More information:
Access the news on Oslo Bors NewsWeb site
Source
Arctic Bioscience AS
Provider
Oslo Børs Newspoint
Company Name
ARCTIC BIOSCIENCE AS
ISIN
NO0010859580
Symbol
ABS
Market
Euronext Growth